Rocaglamide J
- CAS NO.:147059-47-0
- Molecular Weight: 0
- SAFETY DATA SHEET (SDS)
- Update Date: 2023-05-04 17:34:33
What is Rocaglamide J?
The Uses of Rocaglamide J
Rocaglamide J is a derivative of rocaglamide.
What are the applications of Application
Rocaglamide J is a derivative of rocaglamide
Definition
ChEBI: Aglafolin is a heterotricyclic compound based on a 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a and methoxy groups at C-6 and C-8. A platelet aggregation inhibitor found in Aglaia elliptifolia and Aglaia odorata. It has a role as a metabolite and a platelet aggregation inhibitor. It is an organic heterotricyclic compound and a methyl ester.
Safety information for Rocaglamide J
New Products
Dibenzoyl-L-tartaric acid Anhydrous (Resolution Reagent) Cis-Tosylate Dibenzo[b,f][1,4]thiazepin-11(10H)-one 1,2,3,9-Tetrahydro-9-Methyl-4H-Carbazole-4-One 1-(4-methoxyphenyl)-4-(4-Nitrophenyl)Piperazine (IT-1) BOC Piperazine 1-Benzhydrylazetane-3-carbonitrile 8-oxa-1,3-diazaspiro[4.5]decane-2,4-dione (±)-amino(2-fluorophenyl)acetic acid 2-(2-Chlorophenyl)glycine AMINO-(3-CHLORO-PHENYL)-ACETIC ACID 2'-Fluoroacetophenone METHANOL-D1(OD) TERTIARY BUTANOL-D9 N-ETHYL-D5-AMINE HYDROCHLORIDE BENZOIC ACID-D CHLOROFORM-D TOLUENE-D3 Trans,trans muconic acid HC Blue-16 4-Amino-2-chloro-6,7-dimethoxyquinazoline Ethyl 4,5-bis(2-methoxyethoxy)-2-nitrobenzoate 2,3-Dimethoxypyridine 1-(3-Chlorophenyl)piperazine hydrochlorideYou may like
-
Product IntroductionView Details -
Product InrtroductionView Details -
DGO24View Details -
DGO25View Details -
DGO29View Details -
DGO32View Details -
DGO36View Details -
DGO37View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
